BLCO Stock Recent News
BLCO LATEST HEADLINES
Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch + Lomb Corp.'s stock soared 10% early Wednesday, after the vision-care company's adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024.
Besides Wall Street's top -and-bottom-line estimates for Bausch + Lomb (BLCO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Bausch + Lomb (BLCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch + Lomb (BLCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brent Saunders - Chairman and Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Young Li - Jefferies Craig Bijou - Bank of America Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Douglas Miehm - RBC Capital Markets Operator Good morning and welcome to the Bausch + Lomb Third Quarter 2023 Earnings Call. All participants will be in a listen-only mode.
Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.29 per share a year ago.
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.24 per share a year ago.
Brent Saunders led Bausch + Lomb Corporation when it was sold to Valeant Pharmaceuticals. He later led and sold competitor Allergan to AbbVie.